Granted Patent
B2
US 12,391,740 · App. 17/337,018 · Granted Aug 19, 2025
Compositions and methods for treating cancer with anti-BCMA immunotherapy
Inventors:
Dina Schneider (Potomac, MD); Zhongyu Zhu (Frederick, MD); Boro Dropulic (Ellicott City, MD); Bang Khoa Vu (Frederick, MD); Leah Marie Alabanza (Montgomery Village, MD)
Assignee:
LENTIGEN TECHNOLOGY, INC.
C07K14/7051A61K40/11A61K40/31A61K40/4202A61K40/4215A61P35/00C07K14/70517C07K14/70521C07K14/70578C07K16/2878C12N5/0636A61K2239/31A61K2239/48C12N15/63
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims (23)
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 78.
2. A vector comprising the nucleic acid molecule of claim 1 .
3. The vector of claim 2 , wherein the vector is selected from the group consisting of a DNA vector, an RNA vector, a plasmid vector, a cosmid vector, a herpes virus vector, a measles virus vector, a lentivirus vector, an adenoviral vector, and a retrovirus vector.
4. The vector of claim 2 , further comprising a promoter.
5. The vector of claim 4 , wherein the promoter is an inducible promoter, a constitutive promoter, a tissue specific promoter, a suicide promoter or any combination thereof.
6. An isolated cell comprising the vector of claim 2 .
7. The isolated cell of claim 6 , wherein the cell is a T cell.
8. The isolated cell of claim 6 , wherein the T cell is a CD8 + T cell.
9. The isolated cell of claim 6 , wherein the cell is a human cell.
10. The isolated nucleic acid molecule of claim 1 , wherein the isolated nucleic acid molecule encodes a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 98 or SEQ ID NO: 102.
11. A pharmaceutical composition comprising an anti-tumor effective amount of a population of isolated human T cells, wherein the T cells comprise a nucleic acid sequence that encodes a CAR encoded by the isolated nucleic acid molecule of claim 1 , and wherein the T cells are T cells of a human having a cancer.
12. The pharmaceutical composition of claim 11 , wherein the T cells are T cells of a human having a hematological cancer.
13. The pharmaceutical composition of claim 12 , wherein the hematological cancer is leukemia or lymphoma.
14. The pharmaceutical composition of claim 13 , wherein the leukemia is acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), acute lymphoblastic T cell leukemia (T-ALL), or acute lymphoblastic B cell leukemia (B-ALL).
15. The pharmaceutical composition of claim 13 , wherein the lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma.
16. The pharmaceutical composition of claim 12 , wherein the hematological cancer is multiple myeloma.
17. The pharmaceutical composition of claim 11 , wherein the human cancer is an oral and pharynx cancer, a digestive system cancer, a respiratory system cancer, a bone and joint cancer, a soft tissue cancer, a skin cancer, a pediatric cancer, a cancer of the central nervous system, a cancer of the breast, a cancer of the genital system, a cancer of the urinary system, a cancer of the eye and orbit, a cancer of the endocrine system, and a cancer of the brain.
18. A CAR encoded by the isolated nucleic acid molecule of claim 1 .
19. A method of making a cell comprising transducing a T cell with a vector of claim 2 .
20. A method of generating a population of RNA-engineered cells comprising introducing an in vitro transcribed RNA or a synthetic RNA into a cell in vitro, wherein the RNA comprises the nucleic acid molecule of claim 1 .
21. A process for producing a CAR-expressing cell, the process comprising introducing the isolated nucleic acid of claim 1 into an isolated cell.
22. The process for producing a CAR-expressing cell according to claim 21 , wherein the cell is an isolated T cell or an isolated cell population containing a T cell.
23. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 98 or SEQ ID NO: 102.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 17, 2021
From: SCHNEIDER, DINA; ZHU, ZHONGYU; DROPULIC, BORO; VU, BANG KHOA; ALABANZA, LEAH MARIE
To: LENTIGEN TECHNOLOGY, INC.
Reel/Frame 057198/0330 →
Continuity (3)
Provisional Application
62854574
· May 30, 2019
References Cited (122)
US 3060165A
· Craig et al.
· 1962
[cited by applicant]
US 3896111A
· Kupchan et al.
· 1975
[cited by applicant]
US 4137230A
· Hashimoto et al.
· 1979
[cited by applicant]
US 4151042A
· Higashide et al.
· 1979
[cited by applicant]
US 4235871A
· Papahadjopoulos et al.
· 1980
[cited by applicant]
US 4248870A
· Miyashita et al.
· 1981
[cited by applicant]
US 4256746A
· Miyashita et al.
· 1981
[cited by applicant]
US 4260608A
· Miyashita et al.
· 1981
[cited by applicant]
US 4265814A
· Hashimoto et al.
· 1981
[cited by applicant]
US 4294757A
· Asai
· 1981
[cited by applicant]
US 4307016A
· Asai
· 1981
[cited by applicant]
US 4308268A
· Miyashita et al.
· 1981
[cited by applicant]
US 4308269A
· Miyashita et al.
· 1981
[cited by applicant]
US 4309428A
· Miyashita et al.
· 1982
[cited by applicant]
US 4313946A
· Powell et al.
· 1982
[cited by applicant]
US 4315929A
· Freedman et al.
· 1982
[cited by applicant]
US 4317821A
· Miyashita et al.
· 1982
[cited by applicant]
US 4322348A
· Asai et al.
· 1982
[cited by applicant]
US 4331598A
· Hasegawa et al.
· 1982
[cited by applicant]
US 4361650A
· Asai et al.
· 1982
[cited by applicant]
US 4362663A
· Kida et al.
· 1982
[cited by applicant]
US 4364866A
· Asai et al.
· 1982
[cited by applicant]
US 4371533A
· Akimoto et al.
· 1983
[cited by applicant]
US 4424219A
· Hashimoto et al.
· 1984
[cited by applicant]
US 4450254A
· Isley et al.
· 1984
[cited by applicant]
US 4501728A
· Geho et al.
· 1985
[cited by applicant]
US 4689401A
· Ferris
· 1987
[cited by applicant]
US 4837028A
· Allen
· 1989
[cited by applicant]
US 4880935A
· Thorpe
· 1989
[cited by applicant]
US 4902505A
· Pardridge et al.
· 1990
[cited by applicant]
US 4957735A
· Huang et al.
· 1990
[cited by applicant]
US 5004697A
· Pardridge et al.
· 1991
[cited by applicant]
US 5019369A
· Presant et al.
· 1991
[cited by applicant]
US 5055303A
· Riley, Jr. et al.
· 1991
[cited by applicant]
US 5079163A
· Piatak, Jr. et al.
· 1992
[cited by applicant]
US 5188837A
· Domb
· 1993
[cited by applicant]
US 5208020A
· Chari et al.
· 1993
[cited by applicant]
US 5208021A
· Johnson et al.
· 1993
[cited by applicant]
US 5254342A
· Shen et al.
· 1993
[cited by applicant]
US 5268164A
· Kozarich et al.
· 1993
[cited by applicant]
US 5271961A
· Mathiowitz et al.
· 1993
[cited by applicant]
US 5413797A
· Khan et al.
· 1995
[cited by applicant]
US 5416064A
· Chari et al.
· 1995
[cited by applicant]
US 5506206A
· Kozarich et al.
· 1996
[cited by applicant]
US 5514670A
· Friedman et al.
· 1996
[cited by applicant]
US 5534496A
· Lee et al.
· 1996
[cited by applicant]
US 5792458A
· Johnson et al.
· 1998
[cited by applicant]
US 6441163B1
· Chari et al.
· 2002
[cited by applicant]
EP 0425235
· 1996
[cited by applicant]
WO WO2004010957
· 2004
[cited by applicant]
WO WO2020092848
· 2020
[cited by applicant]
Attal et al., “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma,” New England Journal of Medicine, Jul. 11, 1996, 335:91-99.
[cited by applicant]
Avery et al., “BAFF selectively enhances the survival of plasmablasts generated from human memory B cells,” The Journal of clinical investigation, Jul. 15, 2003, 112(2):286-297.
[cited by applicant]
Brown et al., “Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T cells,” Clinical Cancer Research, Apr. 15, 2012, 18(8):2199-2209.
[cited by applicant]
Child et al., “High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,” New England Journal of Medicine, May 8, 2003, 348(19):1875-1883.
[cited by applicant]
Clay et al., “Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity,” The Journal of Immunology, Jul. 1, 1999, 163(1):507-513.
[cited by applicant]
D'Aloia, “CAR-T cells: the long and winding road to solid tumors,” Cell Death and Disease, 2018, pp. 1-12.
[cited by applicant]
Deckert et al., “SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies,” Clinical Cancer Research, Sep. 1, 20…
[cited by applicant]
De-Xiu et al., “Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma, ” Oncotarget, May 25, 2018, 9(40):25764.
[cited by applicant]
Di Stasi et al., “Inducible apoptosis as a safety switch for adoptive cell therapy,” New England Journal of Medicine, Nov. 3, 2011, 365:1673-1683.
[cited by applicant]
Fermand et al., “Single versus tandem high dose therapy (HDT) supported with autologous stem cell transplantation using unselected or CD-34-enriched ABSC: results of a two by two designed randomized trial in 230 young p…
[cited by applicant]
Foster et al., “Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor,” Journal of Immunotherapy (Hagerstown, Md.: 1997), Jun. 2008, 31(5):500-505.
[cited by applicant]
Fults et al., “Sustained-release of urease from a poloxamer gel matrix,” PDA Journal of Pharmaceutical Science and Technology, Mar. 1, 1990, 44(2):58-65.
[cited by applicant]
Funatsu et al., “The complete amino acid sequence of the A-chain of abrin-a, a toxic protein from the seeds of Abrus precatorius,” Agricultural and Biological Chemistry, Apr. 1, 1988, 52(4):1095-1097.
[cited by applicant]
Gillespie et al., “Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer,” Annals of Oncology, Jun. 1, 2000, 11(6…
[cited by applicant]
Goyal et al., “Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins,” Biochemical Journal, Jan. 15, 2000, 345(2):247-254.
[cited by applicant]
Haso et al., “Anti-CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia,” Blood, Feb. 14, 2013 121 (7):1165-1174.
[cited by applicant]
Hegde et al., “Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma,” Molecular Therapy, Nov. 1, 2013, 21(11):2087-2101.
[cited by applicant]
Ijntema et al., “Hydroxyapatite microcarriers for biocontrolled release of protein drugs,” International Journal of Pharmaceutics, Dec. 5, 1994, 112(3):215-224.
[cited by applicant]
Johnson et al., “Anti-tumor activity of CC49-doxorubicin immunoconjugates,” Anticancer Research, Aug. 1995, 15(4):1387-1393.
[cited by applicant]
Johnston et al., “Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice,” Pharmaceutical Research, Mar. 1, 1992, 9(3):425-434.
[cited by applicant]
Kloss et al., “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells,” Nature Biotechnology, Jan. 2013, 31(1):71-75.
[cited by applicant]
Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood, The Journal of the Ameri…
[cited by applicant]
Krishnan et al., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assi…
[cited by applicant]
Kyle et al., “A long-term study of prognosis in monoclonal gammopathy of undetermined significance,” New England Journal of Medicine, Feb. 21, 2002, 346(8):564-9.
[cited by applicant]
Kyle et al., “Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma,” New England Journal of Medicine, Jun. 21, 2007, 356(25):2582-90.
[cited by applicant]
Kyle et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” Clinic Proceedings, Jan. 1, 2003, 78(1):21-33.
[cited by applicant]
Laird et al., “Isolation and characterization of tox mutants of corynebacteriophage beta,” Journal of Virology, Jul. 1, 1976, 19(1):220-7.
[cited by applicant]
Landgren et al., “Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study,” Blood, May 28, 2009, 113(22):5412-7.
[cited by applicant]
Landgren et al., “Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey,” Leukemia, Jul. 2014. 28(7):1537…
[cited by applicant]
Langer, “Polymer-controlled drug delivery systems,” Accounts of Chemical Research, Oct. 1, 1993, 26(10):537-42.
[cited by applicant]
Lanitis et al., “Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo,” Cancer Immunology Research, Jul. 1, 2013, 1(1):43-53.
[cited by applicant]
Lau et al., “Conjugation of doxorubicin to monoclonal anti-carcinoembryonic antigen antibody via novel thiol-directed cross-linking reagents,” Bioorganic & Medicinal Chemistry, Oct. 1, 1995, 3(10):1299-304.
[cited by applicant]
Lau et al., “Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro,” Bioorganic & Medicinal Chemistry, Oct. 1, 1995, 3(10):1305-12.
[cited by applicant]
Lee et al., “Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 21, alpha 31, beta II, gamma II and delta II,” The Journ…
[cited by applicant]
Lehner et al., “Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection,” PloS one, Feb. 15, 2012, 7(2):e31210, 12 pages.
[cited by applicant]
Long et al., “Lessons learned from a highly-active CD22-specific chimeric antigen receptor,” Oncoimmunology, Apr. 1, 2013, 2(4):e23621, 3 pages.
[cited by applicant]
Lonial et al., “Elotuzumab therapy for relapsed or refractory multiple myeloma,” New England Journal of Medicine, Aug. 13, 2015, 373(7):621-31.
[cited by applicant]
Lonial et al., “Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius),” Journal of Clinical Oncology, Jun. 2015…
[cited by applicant]
Ma et al., “Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma,” Annals of Hematology, Apr. 5, 2019, 98(4):813-22.
[cited by applicant]
McNamara et al., American Society of Hematology 55th Annual Meeting and Exposition, New Orleans, Louisiana, USA, Drugs of Today, Dec. 2013, 49(12), abstract only, 1 page.
[cited by applicant]
“Morgan and Schambach, Engineering CAR-T Cells for Improved Function Against Solid Tumors, Frontiers in Immunology, 2018, pp. 1-11”.
[cited by applicant]
Nicolson et al., “The interaction of Ricinus communis agglutinin with normal and tumor cell surfaces,” Biochimica et Biophysica Acta (BBA)-Biomembranes, May 9, 1972, 266(2):543-547.
[cited by applicant]
Olsnes et al., “Mechanism of action of the toxic lectins abrin and ricin,” Nature, Jun. 1974, 249(5458):627-631.
[cited by applicant]
Olsnes et al., “Ricin and ricinus agglutinin, toxic lectins from castor bean,” Methods in Enzymology, Jan. 1, 1978, 50:330-335.
[cited by applicant]
Phillips et al., “Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate,” Cancer Research, Nov. 15, 2008, 68(22):9280-9290.
[cited by applicant]
Plesner et al., “Daratumumab for the treatment of multiple myeloma,” Frontiers in Immunology, Jun. 4, 2019, 9:1228, 7 pages.
[cited by applicant]
Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” New England Journal of Medicine, Aug. 25, 2011, 365:725-733.
[cited by applicant]
Rajkumar et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, Dec. 15, 2005, 106(13):4050-3.
[cited by applicant]
Rathoreet al., “Overproduction of fungal ribotoxin α-sarcin in
[cited by applicant]
Rennert et al., “A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth,” Journal of Experimental Medicine, Apr. 4, 2000, 192(11):1677-1684.
[cited by applicant]
Sbah et al., “B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches,” Leukemia, Apr. 2020, 34(4):985-1005.
[cited by applicant]
Smith et al., “Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector,” Molecular Therapy, Jun. 6, 2018, 26(6):1447-56, 38 pages.
[cited by applicant]
Sommer et al., “ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for the treatment of multiple myeloma,” Blood, Nov. 29, 2018, 132(Supplement 1): 591, 3 pages.
[cited by applicant]
Sridhar and Petrocca, “Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy,” Cancers, 2017, pp. 1-10.
[cited by applicant]
Stirpe et al., “Ribosome-inactivating proteins from plants: present status and future prospects,” Bio/Technology, Apr. 1992, 10(4):405-12.
[cited by applicant]
Suzuki et al., “Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction,” Nature Biotechnology, Mar. 1999, 17(3):265-270.
[cited by applicant]
Thompson et al., “BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population,” The Journal of Experimental Medicine, Jul. 3…
[cited by applicant]
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo,” Cancer Research, Nov. 15, 1987, 47(22):5924-5931.
[cited by applicant]
Wawrzynczak et al., “Methods for preparing immunotoxins: effect of the linkage on activity and stability,” Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer, 1987, 28-55.
[cited by applicant]
Yu et al., “The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum,” Proceedings of the National Academy of Sciences, Jun. 11, 2002, 99(12):7968-7973.
[cited by applicant]
Yvon et al., “Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells,” Clinical Cancer Research, Sep. 15, 2009, 15(18):5852-5860.
[cited by applicant]
Zhao et al., “A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity,” The Journal of Immunology, Nov. 1, 2009, 183(9):5…
[cited by applicant]
Zhao et al., “Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines,” The Journal of Immunology, Apr. 1, 2005, 174(7):4415-4423.
[cited by applicant]